303 related articles for article (PubMed ID: 23381010)
1. Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease-mineral bone disorders (CKD-MBD) in children.
Wesseling-Perry K; Salusky IB
Pediatr Nephrol; 2013 Apr; 28(4):617-25. PubMed ID: 23381010
[TBL] [Abstract][Full Text] [Related]
2. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study.
Gallieni M; De Luca N; Santoro D; Meneghel G; Formica M; Grandaliano G; Pizzarelli F; Cossu M; Segoloni G; Quintaliani G; Di Giulio S; Pisani A; Malaguti M; Marseglia C; Oldrizzi L; Pacilio M; Conte G; Dal Canton A; Minutolo R
J Nephrol; 2016 Feb; 29(1):71-8. PubMed ID: 25986389
[TBL] [Abstract][Full Text] [Related]
3. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
4. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
5. Interventions for metabolic bone disease in children with chronic kidney disease.
Hahn D; Hodson EM; Craig JC
Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD008327. PubMed ID: 26561037
[TBL] [Abstract][Full Text] [Related]
6. CKD-MBD: impact on management of kidney disease.
Ogata H; Koiwa F; Kinugasa E; Akizawa T
Clin Exp Nephrol; 2007 Dec; 11(4):261-268. PubMed ID: 18085385
[TBL] [Abstract][Full Text] [Related]
7. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).
Ruospo M; Palmer SC; Natale P; Craig JC; Vecchio M; Elder GJ; Strippoli GF
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD006023. PubMed ID: 30132304
[TBL] [Abstract][Full Text] [Related]
8. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
[TBL] [Abstract][Full Text] [Related]
9. Progress in pharmacotherapy for the treatment of hyperphosphatemia in renal failure.
Cernaro V; Longhitano E; Calabrese V; Casuscelli C; Di Carlo S; Spinella C; Gembillo G; Santoro D
Expert Opin Pharmacother; 2023; 24(15):1737-1746. PubMed ID: 37527180
[TBL] [Abstract][Full Text] [Related]
10. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
11. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076
[TBL] [Abstract][Full Text] [Related]
12. Trends of elevated parathormone serum titers in hemodialysis patients on intensive therapy for bone disease: a multicenter study.
Karkar A; Sinha AK; Abdelrahman M; Mushtaque F; Awn NM; Qadi Y; Nassar M; Algareeb A; Taha MI; Abdulkader M; Sabry A; Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2014 Nov; 25(6):1166-77. PubMed ID: 25394432
[TBL] [Abstract][Full Text] [Related]
13. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
Bernardor J; De Mul A; Bacchetta J; Schmitt CP
Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
[TBL] [Abstract][Full Text] [Related]
14. Multinational observational study on clinical practices and therapeutic management of mineral and bone disorders in patients with chronic kidney disease stages 4, 5, and 5D: The OCEANOS study.
Shaheen FA; Kurpad R; Al-Sayyari AA; Souqiyyeh MZ; Aljubori H; El Baz T; Kashif W; Tuganbekova S; Kabulbayev K; Jarraya F; Nafar M
Saudi J Kidney Dis Transpl; 2016 Mar; 27(2):290-304. PubMed ID: 26997382
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of chronic kidney disease and mineral bone disorder.
Barreto FC; de Oliveira RA; Oliveira RB; Jorgetti V
Expert Opin Pharmacother; 2011 Dec; 12(17):2627-40. PubMed ID: 22017388
[TBL] [Abstract][Full Text] [Related]
16. [Treatment for CKD-MBD(Chronic Kidney Disease-Mineral and Bone Disorder)].
Iwashita Y; Iwashita Y; Ito T; Shigematsu T
Clin Calcium; 2016 Feb; 26(2):259-67. PubMed ID: 26813506
[TBL] [Abstract][Full Text] [Related]
17. Treatment of hyperphosphatemia: the dangers of aiming for normal PTH levels.
Haffner D; Leifheit-Nestler M
Pediatr Nephrol; 2020 Mar; 35(3):485-491. PubMed ID: 31823044
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
19. The future of phosphate binders: a perspective on novel therapeutics.
Cernaro V; Santoro D; Lucisano S; Nicocia G; Lacquaniti A; Buemi M
Expert Opin Investig Drugs; 2014 Nov; 23(11):1459-63. PubMed ID: 25243756
[TBL] [Abstract][Full Text] [Related]
20. Integral pharmacological management of bone mineral disorders in chronic kidney disease (part I): from treatment of phosphate imbalance to control of PTH and prevention of progression of cardiovascular calcification.
Bover J; Ureña-Torres P; Lloret MJ; Ruiz-García C; DaSilva I; Diaz-Encarnacion MM; Mercado C; Mateu S; Fernández E; Ballarin J
Expert Opin Pharmacother; 2016 Jun; 17(9):1247-58. PubMed ID: 27156993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]